Placebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathy

OBJECTIVE: To determine whether rituximab 375 mg/m(2) was efficacious in patients with immunoglobulin M (IgM) anti-myelin–associated glycoprotein antibody demyelinating neuropathy (IgM anti-MAG demyelinating neuropathy). METHODS: Fifty-four patients with IgM anti-MAG demyelinating neuropathy were en...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Léger, Jean-Marc, Viala, Karine, Nicolas, Guillaume, Créange, Alain, Vallat, Jean-Michel, Pouget, Jean, Clavelou, Pierre, Vial, Christophe, Steck, Andreas, Musset, Lucile, Marin, Benoit
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3721095/
https://ncbi.nlm.nih.gov/pubmed/23667063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e318296e92b
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados